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A B S T R A C T
Background
Approximately 20% of stroke patients experience clinically significant levels of anxiety at some point after stroke. Physicians can treat
these patients with antidepressants or other anxiety-reducing drugs, or both, or they can provide psychological therapy. This review
looks at available evidence for these interventions. This is an update of the review first published in October 2011.
Objectives
The primary objective was to assess the effectiveness of pharmaceutical, psychological, complementary, or alternative therapeutic
interventions in treating stroke patients with anxiety disorders or symptoms. The secondary objective was to identify whether any of
these interventions for anxiety had an effect on quality of life, disability, depression, social participation, caregiver burden, or risk of
death.
Search methods
We searched the trials register of the Cochrane Stroke Group (January 2017). We also searched the Cochrane Central Register of
Controlled Trials (CENTRAL; the Cochrane Library; 2017, Issue 1: searched January 2017); MEDLINE (1966 to January 2017)
in Ovid; Embase (1980 to January 2017) in Ovid; the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1937
to January 2017) in EBSCO; and PsycINFO (1800 to January 2017) in Ovid. We conducted backward citation searches of reviews
identified through database searches and forward citation searches of included studies. We contacted researchers known to be involved
in related trials, and we searched clinical trials registers for ongoing studies.
Selection criteria
We included randomised trials including participants with a diagnosis of both stroke and anxiety for which treatment was intended to
reduce anxiety. Two review authors independently screened and selected titles and abstracts for inclusion.
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Data collection and analysis
Two review authors independently extracted data and assessed risk of bias. We performed a narrative review. We planned to do a meta-
analysis but were unable to do so as included studies were not sufficiently comparable.
Main results
We included three trials (four interventions) involving 196 participants with stroke and co-morbid anxiety. One trial (described as a
’pilot study’) randomised 21 community-dwelling stroke survivors to four-week use of a relaxation CD or to wait list control. This
trial assessed anxiety using the Hospital Anxiety and Depression Scale and reported a reduction in anxiety at three months among
participants who had used the relaxation CD (mean (standard deviation (SD) 6.9 (± 4.9) and 11.0 (± 3.9)), Cohen’s d = 0.926, P value
= 0.001; 19 participants analysed).
The second trial randomised 81 participants with co-morbid anxiety and depression to paroxetine, paroxetine plus psychotherapy, or
standard care. Mean levels of anxiety severity scores based on the Hamilton Anxiety Scale (HAM-A) at follow-up were 5.4 (SD ± 1.7),
3.8 (SD ± 1.8), and 12.8 (SD ± 1.9), respectively (P value < 0.01).
The third trial randomised 94 stroke patients, also with co-morbid anxiety and depression, to receive buspirone hydrochloride or
standard care. At follow-up, the mean levels of anxiety based on the HAM-A were 6.5 (SD ± 3.1) and 12.6 (SD ± 3.4) in the two groups,
respectively, which represents a significant difference (P value < 0.01). Half of the participants receiving paroxetine experienced adverse
events that included nausea, vomiting, or dizziness; however, only 14% of those receiving buspirone experienced nausea or palpitations.
Trial authors provided no information about the duration of symptoms associated with adverse events. The trial of relaxation therapy
reported no adverse events.
The quality of the evidence was very low. Each study included a small number of participants, particularly the study of relaxation
therapy. Studies of pharmacological agents presented details too limited to allow judgement of selection, performance, and detection
bias and lack of placebo treatment in control groups. Although the study of relaxation therapy had allocated participants to treatment
using an adequate method of randomisation, study recruitment methods might have introduced bias, and drop-outs in the intervention
group may have influenced results.
Authors’ conclusions
Evidence is insufficient to guide the treatment of anxiety after stroke. Further well-conducted randomised controlled trials (using
placebo or attention controls) are required to assess pharmacological agents and psychological therapies.
P L A I N L A N G U A G E S U M M A R Y
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Review question
To determine whether any treatments might reduce the symptoms of anxiety, and subsequently improve quality of life, for people who
have had a stroke.
Background
Anxiety after stroke occurs frequently and can be treated with antidepressants or other anxiety-reducing drugs, or both, or with
psychological therapy.
Study characteristics
Evidence is current to January 2017. We found three studies with 196 stroke survivors who had received a diagnosis of anxiety. One
study assessed the effect of a relaxation CD used five times a week for one month for participants with a diagnosis of anxiety. Two
studies assessed the use of antidepressants in participants who had both anxiety and depression.
Key results
One study found that participants were less anxious three months after using a relaxation CD when compared with those who were
given no therapy. One study reported that participants were less anxious when treated with an antidepressant medicine (paroxetine),
or with paroxetine and psychotherapy, than with standard care. This study reported that half of the participants receiving paroxetine
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experienced side effects that included nausea, vomiting, or dizziness. The third study also reported that participants were less anxious
when treated with an antidepressant (buspirone hydrochloride) than with standard care, and only 14% of those receiving buspirone
hydrocholoride reported nausea or palpitations.
Quality of the evidence
We judged that the quality of this evidence was very low. Studies were few and each included a small number of participants. Studies
assessing antidepressants did not include comparison with a placebo drug, and information in both study reports was insufficient
to permit assessment of whether other biases had been introduced. The study of relaxation therapy was very small, with loss of two
participants who used the CD, and the study recruitment process may have attracted participants who had a positive bias towards
psychological therapies.
Conclusion
Current evidence is insufficient to guide the treatment of anxiety after stroke. Additional well-conducted randomised trials are needed.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Interventions for treating anxiety after stroke
Patient or population: stroke survivors with anxiety
Settings: out of hospital
Intervention: pharmacological or psychological treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Interventions
Proportion of stroke
patients without clini-
cal diagnosis of an anx-
iety disorder
See comment See comment Not est imable 19
(1 study)
⊕©©©
very lowa,b
Clinical anxiety at 3
months: 4/ 9 in interven-
t ion group no longer had
anxiety, 1/ 10 in control
group no longer had anx-
iety
Proportion of stroke
patients scoring out-
side anxiety range; or
changes from baseline
on an anxiety rating
scale
See comment See comment Not est imable 196
(3 studies)
⊕©©©
very lowc,d
Stat ist ically signif icant
dif f erence in anxiety
scores on HADS-A scale
at 3 months, with reduc-
t ion in anxiety for those
using therapeut ic CD (P
value = 0.001); stat is-
t ically signif icant dif f er-
ences in HAM-A scores
at 6 weeks and 4 weeks
with reduced anxiety for
those taking paroxet ine
and paroxet ine with psy-
chological therapy and
those taking buspirone,
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respect ively (P value < 0.
01)
Co-morbid depression See comment See comment Not est imable 175
(2 studies)
See comment Reduct ion in depression
symptoms according to
HAM-D at 6 weeks and at
4 weeks for those taking
paroxet ine and paroxe-
t ine with psychological
therapy and those taking
buspirone, respect ively
Quality of life - not re-
ported
See comment See comment Not est imable - See comment Outcome not reported in
any study
Social activities - not
reported
See comment See comment Not est imable - See comment Outcome not reported in
any study
Activities of daily living See comment See comment Not est imable 81
(1 study)
⊕©©©
very lowb,e
Improvement in act ivi-
t ies of daily living in all
groups, but greatest im-
provement in those tak-
ing paroxet ine with psy-
chological therapy
Principal caregiver
burden - not reported
See comment See comment Not est imable - See comment Outcome not reported in
any study
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI)
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
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aStudy was unblinded, with further risks of recruitment bias and drop-outs. Downgraded one level for risk of bias
bOnly one study with small number of part icipants, downgraded two levels for imprecision
cLim ited detail in Wang 2005 and Zhang 2005 for ef fect ive assessment of bias; lack of blinding, risks of recruitment bias, and
drop-outs in Golding 2016. Downgraded two levels for risk of bias
dOnly three studies with few part icipants, all with dif f erent intervent ions that are not comparable. Downgraded one level for
indirectness and one level for imprecision
eLim ited detail in studies, unable to ef fect ively assess risk of bias; downgraded one level
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Stroke and anxiety disorders are major public health problems. Al-
though stroke is the leading cause of adult disability (Department
of Health 2007; Intercollegiate Stroke Working Party 2012), anx-
iety is the most common mental health disorder (Lepine 2002).
Prevalence of anxiety after stroke ranges from 20% to 25%
(Campbell Burton 2013), and it remains a common problem sev-
eral years after the stroke event (Ayerbe 2013; Langhorne 2000).
Anxiety is more common among younger or female people after
stroke, those unable to work after stroke, and those from lower
income backgrounds (Ayerbe 2013; Broomfield 2015; Menlove
2015).
Several distinct types of anxiety disorders are known, such as gen-
eral anxiety disorder (GAD), panic disorder, social phobia, obses-
sive-compulsive disorder (OCD), and post-traumatic stress disor-
der (PTSD). Although categorically different, these disorders share
similar hallmark characteristics of excessive and irrational fear, sub-
jective apprehension, and difficulty and distress in managing daily
tasks (Gelder 2006). Furthermore, although an anxiety disorder is
diagnosed, many individuals experience significant levels of phys-
ical (e.g. heart palpitations, shortness of breath), cognitive (e.g.
feeling of losing control), or behavioural (e.g. avoidance of certain
stimuli) symptoms of anxiety that can affect their daily lives. All
types of anxiety disorders have been observed in stroke patients
(House 1991; Max 2002), and have been shown to have a nega-
tive impact on quality of life (Ahlsio 1984). Co-morbidity with
depression is also very high (Castillo 1993). Studies have found
that depression is more severe and longer lasting in those with
co-morbid anxiety (Shimoda 1998), and stroke patients with co-
morbid anxiety and depression have higher levels of impairment in
activities of daily living, greater cognitive impairment, and fewer
social ties than those with depression alone (Shimoda 1998).
Differentiating between normal worries and emergence of patho-
logical anxiety disorders, or clinically significant levels of anxiety
symptoms, is difficult for several reasons. Advanced age and lim-
ited verbal ability, both of which are common within the stroke
population, increase the difficulty involved in identifying persons
with anxiety (Van Rijswijk 2009). Other practical problems, such
as difficulty accessing specialist mental health services, not pre-
senting for treatment, and lack of clinical guidelines specific to
stroke patients with anxiety problems, mean that individuals may
go untreated (Fernandez 2007).
Description of the intervention
We were interested in pharmaceutical, psychological, or any alter-
native therapy whose primary purpose was to treat anxiety disor-
ders or significant levels of anxiety symptoms in stroke patients.
Given the potential diversity of anxiety states, we did not limit
our criteria to an a priori list of therapies. However, we did expect
to find studies that treated anxiety according to evidence-based
guidelines, such as those recommended by the National Institute
for Health and Clinical Excellence (NICE 2011), which outline
pharmaceutical and psychological interventions that can be used
to treat members of the general population with specific anxiety
disorders. To our knowledge, no specific guidelines have been de-
veloped for the treatment stroke patients with anxiety.
Pharmaceutical therapies
Several classes of drugs can be used to treat anxiety disorders.
These drugs vary according to the neurotransmitters that they are
purported to affect.
Selective serotonin reuptake inhibitors (SSRIs) are a class of an-
tidepressant drugs used to treat anxiety. Serotonin is a neurotrans-
mitter involved in regulating mood. SSRIs, such as fluoxetine, ser-
traline, escitalopram, paroxetine, and citalopram, are commonly
prescribed for panic disorder, OCD, PTSD, and social phobia
(NIMH 2009). Pharmacologically, SSRIs inhibit post-release re-
uptake of serotonin by presynaptic nerve terminals, hence increas-
ing the level of available serotonin in the brain (Craig 2003).
Tricyclic antidepressants (TCAs) (e.g. imipramine) are an older
generation of antidepressant drugs developed in the 1950s; they
have been replaced for the most part by SSRIs. However, TCAs
are still recommended in clinical guidelines for treating GAD and
panic disorder (NICE 2011). TCAs act as serotonin and nore-
pinephrine reuptake inhibitors, which results in increased extra-
cellular concentrations of these neurotransmitters and hence en-
hanced neurotransmission.
Benzodiazepines (e.g. diazepam, alprazolam) are anxiolytics used
to treat GAD and social phobia (Baldwin 2005), and in some in-
stances specific phobia (NICE 2011; NICE 2014). These drugs
enhance the effect of the gamma-aminobutyric acid (GABA) neu-
rotransmitter, thereby reducing the somatic symptoms associated
with anxiety, such as muscle tension and insomnia, but they are
recommended only for short-term use.
Zopiclone, zolpidem, and zaleplon (Z-drugs) are hypnotics that
can be prescribed to help patients with the sleep disturbance asso-
ciated with GAD and PTSD (NICE 2005). These drugs behave in
a similar way to benzodiazepines, except they have a shorter half-
life.
Psychological therapies
Various forms of psychological therapies are available for treating
anxiety. They are particularly suited to certain forms of anxiety,
such as social anxiety (NICE 2013), and may be welcomed by
individuals (especially older people) who may prefer not to use
psychotropic drugs. This preference is based on concern about
dependence, prior negative experiences, and the fact that many
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individuals do not view their psychological symptoms as a med-
ical illness. Several forms of psychological therapies are described
below.
Behaviour therapy is based on learning theory and consists of ap-
proaches for developing adaptive ways of behaving. The aim of
behaviour therapy is to treat anxiety through techniques designed
to reinforce desired behaviours while eliminating undesired be-
haviours.
Cognitive therapy is based on the cognitive model, which hypoth-
esises that a person’s emotions and behaviours are influenced by
their perception of events. Hence it is not the situation itself that
determines how people feel but rather the way they construe the
situation (Beck 1979).
Cognitive-behavioural therapy (CBT) incorporates elements from
both cognitive and behavioural therapies with the goal of chang-
ing a person’s thoughts, beliefs, attitudes, and expectations, and
how a person acts (similar to behaviour therapy). It is ’present-
centred’ and directs individuals to identify the current issues that
are causing them distress, with the support of a trained psychologi-
cal practitioner. Individuals talk with their therapist about specific
problems in a structured manner and may be given homework
consisting of activities to be completed before their next session.
CBT is characterised as structured, goal-oriented, and time-lim-
ited (Beck 1997).
Complementary or alternative therapies
Although we cannot provide an exhaustive description of all in-
terventions that can be used to treat anxiety, patients may choose
from amix of alternative therapies. For example, self-helpmanuals
may assist patients in gaining understanding or insight into their
emotional problems and can be used to treat anxiety disorders or
severe symptoms with limited therapist involvement (Van Boeijen
2005). Other therapies such as exercise training, which may act
as a buffer for stress or trigger the release of monoamine neuro-
transmitters, and relaxation therapy, which teaches individuals to
recognise symptoms of anxiety and how to respond to them via a
technique that reduces arousal, have also been used to treat anxiety
(Jorm 2004).
How the intervention might work
Pharamaceutical interventions work by altering the level of cer-
tain neurotransmitters in the brain, and psychological interven-
tions aim to altermaladaptive behaviour and cognition to improve
emotional functioning. Treatments in the complementary and al-
ternative category work through multiple mechanisms. Addition-
ally, patients receiving standard care, or those waiting to receive
an intervention, may experience a reduction in anxiety symptoms
through a placebo effect that is not directly related to the action
of the intervention or treatment.
Why it is important to do this review
Anxiety after stroke has received substantially less attention than
other psychological outcomes by both clinicians and researchers.
Systematic reviews have been carried out to assess the effectiveness
of interventions used to treat depression and emotionalism when
they occur after stroke (Hackett 2008; Hackett 2010). The pre-
vious version of this Cochrane Review included only two small
trials, thus highlighting a gap in the literature and knowledge base
(Campbell Burton 2011). Studies in stroke (Shimoda 1998) and
non-stroke populations (Wittchen 2003) have shown that anxiety
increases the risk and severity of depression. Hence, early treat-
ment of anxiety may reduce the risk of subsequent depression
and its associated adverse consequences. Clinical guidelines for
treating anxiety have been established, but their effectiveness in
stroke populations remains unknown. We chose to evaluate any
intervention whose primary aim was to treat anxiety after stroke,
as evidence suggests diversity among patient preferences (Hyde
2005; Riedel-Heller 2005). We did expect that most of the trials
retrieved would provide pharmaceutical or psychologically based
interventions.
O B J E C T I V E S
The primary objective was to assess the effectiveness of pharma-
ceutical, psychological, complementary, or alternative therapeutic
interventions in treating stroke patients with anxiety disorders or
symptoms. The secondary aimwas to identify whether any of these
interventions for anxiety had an effect on quality of life, disability,
depression, social participation, caregiver burden, or risk of death.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) in which the primary aim
of the intervention was to treat anxiety in people with a clinical
diagnosis of stroke (Hatano 1976) were eligible for inclusion in
this review. Review authors applied no restrictions on language or
study location. We expected eligible trials to compare the effect
of an intervention plus usual care against placebo, a different in-
tervention, or different doses or frequency of interventions. Trials
had to include a placebo or standard care control arm; otherwise
they were not eligible for inclusion.
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Types of participants
All stroke patients enrolled into an RCT must have received a
clinical diagnosis of an anxiety disorder according to the Diag-
nostic and Statistical Manual of Mental Disorders (DSM-III (APA
1980), DSM-III-R (APA 1987), DSM-IV (APA 1994), DSM-
IV-TR (APA 2000)) or had to meet similar diagnostic criteria.
Stroke patients in RCTs deemed to have significant levels of anx-
iety symptoms as established by a predetermined defined cut-off
score on an anxiety screening tool were also eligible. Review au-
thors applied no restrictions on age distribution or gender. Studies
with mixed populations of ischaemic or haemorrhagic stroke were
eligible, but we excluded studies assessing treatment effect in an
exclusively subarachnoid haemorrhage patient population, as the
characteristics, treatment, and management of these patients can
be substantially different from those of other stroke patients. Stud-
ies treating stroke patients for other conditions such as depression,
cognitive impairment, or physical disability were also ineligible,
unless we could determine that all patients had co-morbid anxiety
upon enrolment into the trial and that treatment for anxiety was
one of the main objectives of the trial.
Types of interventions
We evaluated RCTs comparing pharmaceutical interventions ad-
ministered to stroke patients versus placebo or standard care. The
drug had to be administered for the purpose of treating anxiety.
We excluded trials in which drugs were administered for other
purposes, such as neuroprotection. We also evaluated RCTs that
compared psychological interventions versus placebo or standard
care for the purpose of treating anxiety. We expected that these
types of interventions would have a clearly defined psychologi-
cal component; would be structured, delivered, and supervised by
trained staff; and would be time-limited. We excluded interven-
tions whose purpose was to prevent anxiety or simply to provide
information or educate patients. We did not include trials of in-
terventions such as occupational therapy or co-ordinator visita-
tion for stroke support unless they had a definitive psychological
component aimed at treating anxiety.
Types of outcome measures
Primary outcomes
1. Proportion of stroke patients without a clinical diagnosis of
an anxiety disorder according to the DSM (APA 1994) or
another standard diagnostic classification at the end of scheduled
follow-up
2. Proportion of stroke patients scoring outside the anxiety
symptom range (as defined by study authors); or with changed
scores from baseline on an anxiety rating scale or via self-report
at the end of scheduled follow-up
Secondary outcomes
1. Co-morbid depression, as diagnosed by DSM or
determined by a depression rating scale such as the Beck
Depression Inventory (BDI) (Beck 1961), the Hamilton
Depression Scale (HAM-D) (Hamilton 1960), or the
Montgomery-Asberg Depression Rating Scale (Montgomery
1979)
2. Quality of life as measured on scales such as the 36-item
Short Form Questionnaire (SF-36) (Ware 1993)
3. Social activities as measured on scales such as the Frenchay
Activities Index (Wade 1985)
4. Activities of daily living as measured on scales such as the
Barthel Index (Mahoney 1965)
5. Principal caregiver burden as measured by scales such as the
Zarit Caregiver Burden Interview (Zarit 1980)
6. Any adverse consequence resulting from treatment for
anxiety such as drug tolerance, co-dependence on the counsellor,
or death. We also recorded rates of loss to follow-up in different
arms of trials as a possible indicator of treatment acceptability
Search methods for identification of studies
See the ’Specialized Register’ section of the Cochrane Stroke
Group module. We attempted to identify all relevant trials regard-
less of language or publication status, and we arranged translation
of relevant papers when necessary.
Electronic searches
We searched the trials register of the Cochrane Stroke Group (Jan-
uary 2017), the Cochrane Central Register of Controlled Trials
(CENTRAL; the Cochrane Library; 2017, Issue 1: searched Jan-
uary 2017) (Appendix 1); MEDLINE (1966 to January 2017)
in Ovid (Appendix 2); Embase (1980 to January 2017) in Ovid
(Appendix 3); the Cumulative Index to Nursing and Allied
Health Literature (CINAHL; 1937 to January 2017) in EBSCO
(Appendix 4); and PsycINFO (1800 to January 2017) in Ovid
(Appendix 5).
We developed the MEDLINE search strategy with the help of
the Cochrane Stroke Group Information Specialist and adapted
it for use with the other databases. We searched the following
trial registers to identify additional published, unpublished, and
ongoing clinical trials.
1. ClinicalTrials.gov (http://clinicaltrials.gov) (January 2016).
2. World Health Organization (WHO) International Clinical
Trials Registry Portal (http://apps.who.int/trialsearch/)
(September 2016).
3. ISRCTN Registry (http://www.isrctn.com/) (January
2016).
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Searching other resources
We identified reviews from the results of database searches and
conducted backward citation searches for potentially eligible trials.
We used Google Scholar (scholar.google.co.uk) to conduct for-
ward citation searching of included studies. We contacted known
researchers to ask for information on completed and ongoing clin-
ical trials.
Data collection and analysis
Selection of studies
Two review authors (SRL, H-YYC) independently screened all re-
ports yielded by the searches of electronic databases, and excluded
citations that were clearly irrelevant based on title and abstract.
We retrieved the full texts of remaining articles and reviewed them
for inclusion on the basis of eligibility criteria for the review. If
consensus could not be reached, we consulted a third review au-
thor (PK) for adjudication.
Data extraction and management
Two review authors (SRL and H-YYC) independently extracted
data and recorded them on a paper extraction form designed to
capture key information. The two review authors reconciled the
data extraction and entered the data into Review Manager 5 (
RevMan 2014). We recorded core data elements such as study
details, methods, information about participants, and outcomes
for analysis.
Assessment of risk of bias in included studies
We assessed study bias in accordance with the Cochrane tool for
assessing risk of bias (Higgins 2011). This instrument includes six
domainswhereby different types of potential bias can be evaluated,
including sequence generation, allocation concealment, blinding
(of participants, personnel, and outcome assessors), incomplete
outcome data, selective outcome reporting, and other unspecified
types of bias (e.g. conflict of interest). We identified respective
biases from each study and displayed them in a tabular format.
We summarised risks qualitatively and attempted to describe their
impact on research findings.
Measures of treatment effect
We prepared a narrative description of all studies. Included tri-
als measured anxiety using the Hamilton Anxiety Scale (HAM-A)
(Hamilton 1959) and the Hospital Anxiety and Depression Scale
(HADS). The HAM-A, a rating scale that was developed to quan-
tify the severity of anxiety symptoms, is often used in psychotropic
drug evaluation. It consists of 14 items, each defined by a series of
symptoms. Each item is rated on a five-point scale, ranging from
0 (not present) to 4 (severe). Total scores on the HAM-A range
from 0 to 56. A score of 14 or higher has been suggested to in-
dicate clinically significant anxiety (Maier 1988). The HADS is
commonly used to assess levels of patient anxiety and depression.
The HADS evaluates 14 items (seven for anxiety and seven for de-
pression) and uses a scale of 0 to 3 for each item, with a total score
of 21 possible for each subscale (Zigmond 1983). Scores of 8 or
above on either HADS subscale are commonly taken to indicate
clinical significance (Bjelland 2002).
Unit of analysis issues
In the event that outcomes were repeatedly observed in partici-
pants (e.g. follow-up at four and six weeks), we reported the mea-
surement taken at the longest time point post intervention from
each study.
Dealing with missing data
We planned to contact study authors to obtain information about
missing data and, if we could not obtain this, we planned to con-
duct a ’what if ’ sensitivity analysis to explore the impact that miss-
ing data could have on the final outcome.
Assessment of heterogeneity
The intent was tomeasure heterogeneity by using the I2 statistic. If
higher than 50% (a level considered moderate to substantial), we
would have calculated the treatment effect by using the random-
effectsmethod, which assumes that different studies are estimating
different but related intervention effects and so provides a more
conservative intervention effect estimate and wider confidence in-
tervals (DerSimonian 1986).
Assessment of reporting biases
We planned to construct a funnel plot estimate to assess the po-
tential influence of reporting bias if we had included more than
10 studies in the systematic review.
Data synthesis
Two review authors (SRL and H-YYC) independently extracted
data from the included studies. One review author (SRL) entered
data into RevMan (RevMan 2014) and the other (H-YYC) cross-
checked the data entered. Review authors resolved disagreements
by referring to the original study report.
Subgroup analysis and investigation of heterogeneity
Several factors could impact study heterogeneity and effect size.
We initially planned to undertake subgroup analyses on certain
clinically relevant factors, such as specific type of anxiety disorder
(e.g. GAD, social phobia), length of time treatment was adminis-
tered, or length of time since stroke at entry into the trial.
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Sensitivity analysis
To test robustness of findings and examine the degree to which
findings influenced effect size, we planned to analyse data and in-
clude studies that executed allocation concealment, double blind-
ing, and fidelity to administered intervention to the highest stan-
dard.
’Summary of findings’ table
We used the principles of GRADE (Grades of Recommenda-
tion, Assessment, Development and Evaluation Working Group;
Guyatt 2008) to assess the quality of the body of evidence associ-
ated with the following specific outcomes in our review.
1. Proportion of patients without a clinical diagnosis of
anxiety.
2. Proportion of patients scoring outside the anxiety symptom
range; or with change scores from baseline on an anxiety rating
scale.
3. Co-morbid depression.
4. Quality of life.
5. Social activities.
6. Activities of daily living.
7. Principal caregiver burden.
We constructed a ’Summary of findings’ table by using GRADE
software (gradepro.org). The GRADE approach appraises the
quality of the body of evidence according to the extent to which
one can be confident that an estimate of effect or association re-
flects the item assessed. The quality of a body of evidence is based
on within-study risk of bias (methodological quality), directness
of the evidence, heterogeneity of the data, precision of effect esti-
mates, and risk of publication bias.
R E S U L T S
Description of studies
We identified no trials that compared any intervention with
a placebo control. See Characteristics of included studies and
Characteristics of excluded studies.
Results of the search
We identified 4223 records for the 2017 update through electronic
database searches. We contacted three researchers known to be
working in the field, who provided information on their current
work to enable us to assess study eligibility. We identified 20 ad-
ditional records from the Cochrane Stroke Group trials register.
We removed duplicates and sifted 4069 titles and abstracts. We
identified nine reviews for backward citation searching and evalu-
ated potential studies from these reviews, alongside 39 potentially
relevant full-text articles; we identified one study that met the in-
clusion criteria for this review (Golding 2016), in addition to the
two studies in the previous review update (Wang 2005; Zhang
2005). See Figure 1.
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Figure 1. Search flow diagram (from searches conducted for the review update, October 2010 to January
2017).
12Interventions for treating anxiety after stroke (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
Three trials with a total of 196 randomised participants met our
inclusion criteria (Golding 2016; Wang 2005; Zhang 2005).
Golding 2016 conducted what is described as a ’pilot study’ to as-
sess the effectiveness of a self-help relaxation therapy. Participants
were 21 stroke survivors who had anxiety and were living in the
community. After a telephone interview and assessment, interven-
tion group members (11 participants) were sent a self-help auto-
genic relaxation CD; they were asked to follow the instructions on
it five times per week for one month; and they were asked to com-
plete a diary sheet. The control group (10 participants) did not
receive the CD until the end of the study period at three months.
Individuals were excluded if they were unable to complete rating
scales via telephone, had a Telephone Interview Cognitive Score
(TICS) ≤ 20, had significant difficulties with language or were
non-English speaking, had a co-morbid psychiatric disorder other
than an affective disorder, or were currently receiving other psy-
chological interventions. Study investigators determined anxiety
at baseline and at onemonth, twomonths, and threemonths using
theHADS anxiety subscale (HADS-A). They did not measure any
additional outcomes. The mean age of participants was 67.8 years
in the intervention group, and 62.4 years in the control group.
Wang 2005 evaluated the effectiveness of the SSRI paroxetine and
of combination paroxetine and psychotherapy. Eighty-one first-
ever stroke patients who met Chinese Classification and Diag-
nostic Criteria of Mental Disorders (CCMD-3) criteria were ran-
domised to one of the three groups. The first group (27 partici-
pants) received 20 mg of paroxetine per day, and the second group
(27 participants) received the same amount of paroxetine per day
alongwith psychiatrist-administered supportive psychotherapy for
30 to 60 minutes once per week. A parallel control group with
27 participants received routine treatment only. Study authors did
not specify the length of time since stroke at the time of participant
recruitment. Patients who were in a coma or aphasic, had severe
cognitive dysfunction or other serious disease, or who had been
prescribed depression or antipsychotic medications in the three
months before the start of the trial were excluded. Investigators
provided interventions for six weeks and usedHAM-A andHAM-
D scales to assess the severity of anxiety and depression symptoms
at baseline and at two, four, and six weeks during treatment. They
assessed scores on the Barthel Index measuring activities of daily
living at all time points. The mean age of participants was 62.4
years in the drug only group, 64.0 years in the drug plus psy-
chotherapy group, and 63.2 years in the standard care group.
Zhang 2005 examined the effect of the anxiolytic drug bus-
pirone hydrochloride against standard care. Researchers recruited
94 stroke patients with co-morbid anxiety and depression accord-
ing to the CCMD-3. They deemed that individuals in an unstable
condition were ineligible but provided no description of the un-
stable conditions. Investigators administered buspirone for four
weeks to those in the intervention arm of the study at 20 to 30 mg
per dose during the first week and at 40 to 60 mg per dose during
the secondweek. They provided no information about the amount
administered during the third or fourth week. Researchers mea-
sured anxiety and depression using HAM-A and HAM-D scales at
baseline, and at two and four weeks during the intervention. The
mean age of participants was 57.8 years for the intervention group
and 59.2 years for the control group. Study authors reported no
other secondary outcomes of interest.
Excluded studies
We excluded 40 studies after assessing the full text of the arti-
cle during the most recent search. We excluded 24 of these stud-
ies as they used the wrong study design, did not include partic-
ipants who had a diagnosis of stroke, or did not include a treat-
ment aimed at reducing anxiety. Sixteen studies measured anxi-
ety, often alongside depression, and aimed to relieve psycholog-
ical symptoms exclusively or in addition to physical symptoms.
None of these studies required participants to have a clinical diag-
nosis of anxiety for study participation (Aidar 2012; Aidar 2013;
Akerlund 2013; Chaiyawat 2012; Chan 2012; Hoffmann 2015;
Ihle-Hansen 2014; Immink 2014; Jouzi 2010; Karaiskos 2012;
Kongkasuwan 2014; Kulishova 2014; Mikami 2014; Peng 2015;
Wu 2012; Xue 2013). We excluded these key studies and listed
them under Characteristics of excluded studies. In addition, we
excluded eight key trials from the original review (Kimura 2003;
Li 2005; Liu 2004; Mok 2004; Morrison 1998; Rorsman 2006;
Wu 2008; Ye 2006) and reported reasons for exclusion under
Characteristics of excluded studies.
Studies awaiting classification
Four studies are awaiting classification (Doogan 2012; Guilan
2013; Kerr 2014; Yates 2015). These studies were published as
abstracts only, without author contact details. All studies included
participants who were stroke survivors but provided insufficient
detail to establish whether included participants were required to
have a diagnosis of anxiety.
Ongoing studies
We identified no eligible studies in clinical trials registers.
Risk of bias in included studies
Wehave provided a summary of ’Risk of bias’ assessments in Figure
2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Golding 2016 used a random number generator that we judged
to be adequate with low risk of bias. However, details in the paper
were insufficient to show whether allocation of participants was
adequately concealed. Wang 2005 stated that investigators used
simple random sampling, and Zhang 2005 indicated researchers
used a random number list for participants who met the inclu-
sion criteria. However, neither study described the randomisation
process, hence the integrity of sequence generation and allocation
concealment was unclear.
Blinding
It was not possible to blind participants to the study intervention
in Golding 2016, which presented an inevitably high risk of per-
formance and detection bias. NeitherWang 2005 nor Zhang 2005
provided information about blinding. As these studies included
no placebo control group, blinding would likely be possible only
for independent outcome assessors.
Incomplete outcome data
Golding 2016was a small studywith fewbut potentially significant
losses and no intention-to-treat analysis; therefore, we judged this
trial to have high risk of attrition bias. Wang 2005 reported no
loss to follow-up and did not describe adherence to the treatment
protocol. Zhang 2005 reported outcomes for participants who
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remained until study completion. Hence, this study is classified as
an ’available case analysis’.
Selective reporting
We found no evidence of selective outcome reporting in any of the
included trials. Investigators reported all outcomes as described in
the methods section of the full study report. However, we did not
obtain the research protocols, and study authors did not report
clinical trial registration, so we do not know if other outcomes
were measured but not reported.
Other bias
Methods of recruitment in Golding 2016 had increased risk of
bias, as interested participants responded to advertisements in pub-
lications intended for stroke survivors. It is possible that partic-
ipants who contacted the research team had a positive bias to-
wards psychological therapies for treatment of anxiety, although
the study did not assess this potential bias.
Effects of interventions
See: Summary of findings for the main comparison
Interventions for treating anxiety after stroke
It was not appropriate to combine trial data on pharmacological
therapies with data on relaxation therapy; therefore we did not
perform a meta-analysis.
In summary, Golding 2016 found preliminary evidence in this
pilot study that an autogenic relaxation CD may reduce anxi-
ety among stroke survivors living in the community. Wang 2005
found that both paroxetine and paroxetine plus psychotherapy re-
duced the severity of anxiety symptoms as measured by theHAM-
A when compared with standard care. Zhang 2005 found that
buspirone hydrocholoride was effective in reducing anxiety symp-
toms when compared with standard care.
We have described the effectiveness of interventions compared
with standard care in the prespecified outcomes below and have
reported results of the GRADE assessment, with explanations of
decisions for each outcome, in Summary of findings for the main
comparison.
Primary outcomes
Proportion of stroke patients without a clinical diagnosis of
an anxiety disorder
In Golding 2016, fourmembers of the intervention group were no
longer considered to have clinical levels of anxiety at three months,
compared with one participant in the control group. Investiga-
tors reported loss of two participants after randomisation in the
intervention group with no intention-to-treat analysis. Therefore,
results include nine participants in the intervention group and 10
participants in the control group. We judged this evidence as hav-
ing very low quality.
Wang 2005 and Zhang 2005 did not report this outcome.
Proportion of stroke patients scoring outside the anxiety
symptom range; or with changed scores from baseline on an
anxiety rating scale
Golding 2016 measured levels of anxiety at one, two, and three
months post stroke, but, as per the review protocol, we have con-
sidered analysis only at the final time point. At three months post
stroke, mean scores on the HADS-A scale were 6.9 (± standard
deviation (SD) 4.9) in the intervention group, and 11.0 (SD± 3.9)
in the control group, showing a statistically significant difference
(P value = 0.001). Again these results include nine participants in
the intervention group and 10 participants in the control group.
InWang 2005,meanHAM-A anxiety scores at baseline in the drug
only, drug plus psychotherapy, and standard care groups were 14.0
(SD ± 2.8), 13.9 (SD ± 2.9), and 13.8 (SD ± 2.8), respectively.
At six weeks, mean anxiety scores were significantly lower in the
two intervention groups relative to the controls at 5.4 (SD ± 1.7)
and 3.8 (SD ± 1.8) in the drug only and drug plus psychotherapy
groups, but the mean anxiety score was 12.8 (SD ± 1.9) in the
control group. Relative to the standard care group, this represents
58% and 71% lower mean anxiety scores in the paroxetine and
paroxetine plus psychotherapy groups, respectively. Cohen’s d was
4.10 for the paroxetine only group versus the control group, and
4.86 for the paroxetine plus psychotherapy group versus the con-
trol group. Both of these differences were statistically significant
(P value < 0.01).
In Zhang 2005, four weeks after trial initiation, the mean anxiety
score on the HAM-A decreased from 22.7 (SD ± 5.2) to 6.5 (SD
± 3.1) in the intervention group. This decrease was significantly
larger than that seen in the standard care group (P value < 0.01),
for which the mean anxiety score decreased from 22.5 (SD ± 4.3)
to 12.6 (SD ± 3.4) after four weeks. The mean anxiety score in
the intervention group was 50% lower than that in the standard
care group (Cohen’s d effect size = 1.87).
HAM-A scores range from zero to 56; a score greater than 14
indicates mild to moderate anxiety symptoms. Study authors in
Golding 2016 used a lower cut-off of ≥ 6, which they recom-
mended as the most sensitive for a stroke population. On this ba-
sis, the reduction in anxiety scores among intervention groups in
each trial appears to be clinically meaningful. However, by using
GRADE, we judged that all evidence for this outcome was of very
low quality.
Secondary outcomes
Co-morbid depression
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The possible range on the HAM-D is zero to 54, with higher
scores indicating more severe symptoms. In Wang 2005, mean
depression severity scores were 18.2 (SD ± 1.4), 18.8 (SD ± 3.1),
and 18.0 (SD ± 1.3) at baseline in the paroxetine, paroxetine plus
psychotherapy, and standard care groups, respectively. Although
results showed no change in the control group after six weeks
(mean 17.5, SD±1.1), both the drug only group and the drug plus
psychotherapy group had significantly fewer depression symptoms
(mean 10.1, SD ± 1.1; mean 8.9, SD ± 1.2), respectively.
In Zhang 2005, buspirone was effective in significantly reducing
depression symptoms as measured on the HAM-D in the inter-
vention group compared with the control group. The mean de-
pression score decreased from 24.6 (SD ± 4.7) to 8.3 (SD ± 2.8)
in the intervention group, and from 23.4 (SD ± 5.3) to 13.4 (SD
± 2.7) in the standard care group.
We judged that the evidence for this outcome was of very low
quality.
Quality of life
Studies did not report this outcome.
Social activities
Studies did not report this outcome.
Activities of daily living
Only one trial reported changes in functional status as measured
by the Barthel Index of activities of daily living (ADLs) (Wang
2005). Investigators found that ADLs improved significantly in all
three groups of participants, with the greatest improvement noted
in the drug plus psychotherapy group (which increased from 62.0
(SD ± 23.1) to 90.2 (SD ± 7.3)), followed by the drug-only group
(which increased from 60.9 (SD ± 23.9) to 84.3 (SD ± 8.4)), with
standard care controls showing the least improvement (the increase
was from 61.5 (SD ± 24.3) to 78.3 (SD ± 15.0)). We judged the
evidence for this outcome to be of very low quality.
Principal caregiver burden
Studies did not report this outcome.
Adverse consequences
Wang 2005 reported 26 adverse events, all in participants given
paroxetine or paroxetine with psychotherapy; nine participants
given paroxetine reported nausea and vomiting, and five reported
dizziness, 10 participants given paroxetine with psychotherapy re-
ported nausea and vomiting, and two reported dizziness.
In Zhang 2005, three participants reported dizziness and two re-
ported palpitations. Again, all adverse events occurred in the in-
tervention group.
Combining data fromWang 2005 and Zhang 2005 revealed that
intervention agents increased the risk of dizziness (risk ratio, Man-
tel-Haenszel, random-effects 7.32 (95% confidence interval 0.96
to 55.95)). See Analysis 1.1.
In Golding 2016, one participant reported that the training made
his “eyes feel funny”, and participants did not describe any other
adverse consequences of therapy.
Loss to follow-up and intervention fidelity
No participants were lost to follow-up in Wang 2005. However,
in both intervention and control groups, 23% of participants were
lost in Zhang 2005. Reasons given for drop-out in the interven-
tion group were unsatisfactory treatment effect, drug side effects,
and subsequent prescription of benzodiazepines. Recurrent stroke,
prescribing of benzodiazepines, andwithdrawal were reasons given
for loss to follow-up in the control group. Wang 2005 and Zhang
2005 did not report data on intervention fidelity (other than loss
to follow-up). Loss of two participants in the intervention group
in Golding 2016 was due to personal reasons and to a change in
health circumstances; two of the participants in the intervention
group used the CD less than once a week, rather than five times
per week as directed.
D I S C U S S I O N
Summary of main results
We found three published trials and were unable to identify any
ongoing trials. Among the three published trials, anxiety symptom
severity as measured by the Hamilton Anxiety Scale (HAM-A) or
the Hospital Anxiety and Depression Scale (HADS) was the out-
come of interest. None of these studies evaluated clinical anxiety
disorders or included a placebo control group. Study results sug-
gest that both paroxetine and buspirone are effective pharmaco-
logical therapies for treatment of anxiety after stroke. However, in
the absence of a placebo control arm, the true level of effectiveness
is unknown. Combining paroxetine and psychotherapy did not
confer significant additional benefit for stroke patients. Paroxetine
appeared to be well tolerated, as no drop-outs occurred among
participants, but a large proportion experienced symptoms of nau-
sea or dizziness. Buspirone was also effective in reducing anxiety,
but investigators reported substantial loss to follow-up and some
adverse events. Loss to follow-up in the buspirone trial is unusual
as results show an equally high level of drop-out in the control
group. The addition of Golding 2016 to the most recent update
provides limited evidence that relaxation therapy may reduce anx-
iety among stroke survivors.
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Overall completeness and applicability of
evidence
This review was intentionally broad because we suspected that the
literature on interventions used to treat anxiety after stroke was
not as established as for some of the other post-stroke psycholog-
ical conditions. We attempted to collate comprehensive evidence
relevant to the review question by conducting a thorough evidence
search.
In the original review, the two included studies provided very little
information about the populations from which participants were
selected, and we could not ascertain whether the results were gen-
eralisable to the stroke population (Campbell Burton 2011). We
also noted that the inclusion criteria for the two trials included in
the original review required participants to have both anxiety and
depression according to the Chinese Classification and Diagnos-
tic Criteria of Mental Disorders (CCMD-3), and therefore, the
evidence could not be attributable to stroke survivors with anxi-
ety alone. The inclusion of Golding 2016 in this most recent up-
date provided evidence for a more specific community-based pop-
ulation of stroke survivors with anxiety; however, study authors
used a much lower threshold for clinical anxiety with the HAM-
A scale than in previous studies. Indeed, it should be noted that
although the HAM-A is widely used in pharmaceutical studies of
anxiety, it is not appropriate for use as a diagnostic or screening
instrument. The HAM-A focuses primarily on the phobic and
autonomic arousal symptoms of anxiety, and gives little weight to
the psychic symptoms. Given the physical consequences of stroke,
it would be misleading to attribute all physical symptoms solely
to anxiety after stroke. Therefore, the evidence presented in this
review is limited by the measurement scales used to assess anxiety
in this population.
Quality of the evidence
Two studies assessing pharmacological agents provided limited
methodological details for adequate judgement of risk of bias
across all domains. The third study, which assessed relaxation ther-
apy, inevitably had high risk of bias due to the inability to blind
participants to treatment allocation. Clinical trial registration was
lacking in all studies and study sample sizes were small, including
one study with just 21 participants, which reported two drop-outs
and had high risk of recruitment bias. The pharmacological studies
inadequately described comparison groups. In using GRADE to
assess the quality of the evidence, we were particularly concerned
about risk of bias in these studies, as well as the limited number of
studies including few participants. We downgraded the evidence
by two levels for risk of bias and by one or two levels for impre-
cision; we therefore rated the evidence for each reported outcome
in this review as very low.
Potential biases in the review process
To the extent possible, we worked to ensure minimal bias in the
review process.We undertook an extensive literature search guided
by the Cochrane Stroke Group, and we contacted key researchers
in the field to obtain information about studies with a focus on
post-stroke anxiety. Additionally, we did not limit findings to En-
glish language papers. Two review authors independently decided
whether studies should be included and independently extracted
data.
Agreements and disagreements with other
studies or reviews
To our knowledge, no other systematic reviews have examined
interventions used to treat anxiety after stroke.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently, evidence is insufficient to guide practice in treatment
of anxiety after stroke. The pharmaceutical therapies evaluated in-
dicate that, when compared with standard care, medication may
be an effective approach for reducing anxiety symptoms in stroke
patients with co-morbid anxiety and depression. The clinical sig-
nificance of this decrease is unclear, as study authors did not pro-
vide any information about the proportion of study participants
no longer meeting the anxiety criteria. Research indicates that a
reduction of more than 50% on the Hamilton Anxiety Scale is in-
dicative of tangible improvement in the level of anxiety (Ye 2006).
However, the quality of the evidence for pharmaceutical therapies
in this review is very low. The relaxation therapy evaluated in this
review was examined in a small pilot study, and although study
authors reported a statistically significant reduction in anxiety at
three months after use of an autogenic relaxation CD for one
month, risk of bias inherent in the study design was high, and not
all participants used the CD as often as directed.
Implications for research
Given the high prevalence of anxiety after stroke, placebo-con-
trolled or attention-control trials are needed to identify effective
treatments for this condition, as it can have a negative impact on
other aspects of life. Future research evaluating interventions to
treat post-stroke anxiety should assess outcomes such as quality of
life and caregiver burden, as the trials in this review provided no
information on the impact of treatment on any of these outcomes.
It will also be useful for trials to further investigate the effective-
ness of psychological interventions, and for studies to recruit par-
ticipants with anxiety only, as well as those with co-morbid anxi-
ety and depression. Research into the uptake and acceptability of
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psychological interventions for anxiety after stroke would also be
valuable.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Golding 2016
Methods RCT, feasibility study
Participants Location: UK, community setting
21 stroke survivors experiencing anxiety and living in the community, HADS-A ≥ 6
Group 1: 60% male, mean age 67.8 years (SD 7.5)
Group 2: 50% male, mean age 62.4 years (SD 8.4)
Interventions Intervention group 1: 10 participants, self-help autogenic relaxation CD, asked to follow
instructions 5 times per week for 1 month, asked to complete a diary sheet
Intervention group 2: 10 participants, received CD at end of follow-up
Duration: 3 months
Study dates: not stated
Outcomes HADS-A at months 1, 2, and 3
Loss to follow-up: 1 withdrew at 1 week for personal reasons (group 1), not included
in analysis; 1 withdrew after 1 month owing to additional health concerns (group1),
included in analysis
Notes Exclusions: inability to complete rating scales via telephone; TICS ≤ 20; significant
difficulties with language or non-English speaking; co-morbid psychiatric disorder other
than an affective disorder; currently receiving other psychological intervention
Funding sources/declarations of interest: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of a random number generator. Researcher unaware of
group assignment at this stage
Allocation concealment (selection bias) Unclear risk No details
Blinding (performance bias and detection
bias)
Anxiety
High risk Not possible. Participants may have had a positive bias towards
the intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk Evaluated by participant who was not blinded
Selective reporting (reporting bias) Unclear risk Clinical trial registration not reported; therefore not possible to
assess risk of bias
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Golding 2016 (Continued)
Other bias High risk Recruitment methods (advertisement circulated at 97 stroke
survivor groups and placed in a national stroke survivor publi-
cation) may have led to a participant population biased towards
the intervention and proactively seeking support for anxiety
Wang 2005
Methods RCT
Participants Location: China
81 CT/MRI confirmed first ever stroke according to CCMD-3 criteria with co-morbid
anxiety and depression
Group 1: 52% male, mean age 62.4 years (SD 6.1)
Group 2: 52% male, mean age 64.0 years (SD 5.3)
Group 3: 52% male, mean age 63.2 years (SD 5.7)
Interventions Intervention group 1: 27 participants, paroxetine 20 mg daily + routine treatment
Intervention group 2: 27 participants, paroxetine 20 mg daily + routine treatment +
psychiatrist-administered individual supportive psychotherapy (30 to 60 minutes per
week)
Group 3: 27 participants, control group routine treatment only
Duration: 6 weeks
Study dates: March 2002 to September 2009
Outcomes Anxiety (HAM-A), depression (HAM-D), BI at 2, 4, and 6 weeks
Loss to follow-up: none
Adverse events: 26
1. Group 1: (14 total): minor nausea or stomach distension (9), dizziness (5)
2. Group 2: (12 total): minor nausea and vomiting (10), dizziness (2)
3. Group 3: none reported
Other outcomes: neurological impairment (SSS), activities of daily living (BI)
Notes Exclusions: coma, aphasia, severe cognitive dysfunction, other serious diseases, depression
or antipsychotic medications within 3 months, allergic to paroxetine, or bipolar disorder
Funding sources/declarations of interest: no details
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random number list (details not provided)
Allocation concealment (selection bias) Unclear risk Unknown
Blinding (performance bias and detection
bias)
Anxiety
Unclear risk Unknown
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Wang 2005 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Not applicable; data available from all participants recruited to
the study
Selective reporting (reporting bias) Unclear risk All outcomes measured at start of the trial reported at all time
points
Other bias Unclear risk Unknown
Zhang 2005
Methods RCT
Participants Location: China
94 participants (47 each in control and intervention groups) with clinical diagnosis
of stroke according to CCMD-3 criteria and affective disorders (72 included in final
analysis)
Intervention group: 64% male, 57.8 years (SD 6.4)
Control group: 61% male, 59.2 years (SD 5.8)
Interventions Intervention group: 36 participants, buspirone hydrochloride 20 to 30 mg daily in first
week, 40 to 60 mg in second week + routine care
Control group: 36 participants, routine care (no description of routine care)
Duration: 4 weeks
Study dates: May 2001 to June 2002
Outcomes Anxiety (HAM-A) and depression (HAM-D) at 2 and 4 weeks
Loss to follow-up: 22 (11 in each group)
1. Intervention group: 7 withdrew before treatment, 1 unsatisfactory treatment
effects, 2 adverse effects, 1 prescribed benzodiazepines
2. Control group: 6 withdrew before treatment, 1 recurrent stroke, 4 prescribed
benzodiazepines
Adverse effects: 5
1. Intervention group: 3 dizziness and nausea, 2 palpitations
Other outcomes: American Heart Stroke Outcome Classification
Notes Exclusion: patients with unstable conditions
Funding sources/declarations of interest: no details
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
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Zhang 2005 (Continued)
Blinding (performance bias and detection
bias)
Anxiety
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk High number of losses but balanced between groups
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Unclear risk No information provided
BI: Barthel Index
CCMD-3: Chinese Classification of Mental Disorders Version 3
CT: computed tomography
HADS-A: Hospital Anxiety and Depression Scale - anxiety subscale
HAM-A: Hamilton Anxiety Scale
HAM-D: Hamilton Depression Rating Scale
MRI: magnetic resonance imaging
RCT: randomised controlled trial
SD: standard deviation
SSS: Scandinavian Stroke Scale
TICS: Telephone Interview of Cognitive Status
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aidar 2012 RCT, assessing exercise programme on levels of depression and anxiety among stroke survivors. Excluded from
review as participants were not required to have a clinical diagnosis of anxiety to be eligible
Aidar 2013 RCT, assessing exercise programme on levels of depression and anxiety among stroke survivors. Excluded from
review as participants were not required to have a clinical diagnosis of anxiety to be eligible
Akerlund 2013 RCT, assessing rehabilitation programme for stroke survivors to include working memory training. Included
secondary outcome assessment of anxiety but excluded from review as participants were not required to have
a clinical diagnosis of anxiety to be eligible
Chaiyawat 2012 RCT, assessing rehabilitation programme for stroke survivors. Assessment of HADS, although did not report
anxiety scores separately. Excluded from review as participants were not required to have a clinical diagnosis
of anxiety to be eligible
Chan 2012 RCT, assessing yoga for stroke survivors. Includes assessment of anxiety and depression, but excluded from
review as participants were not required to have a clinical diagnosis of anxiety to be eligible
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(Continued)
Hoffmann 2015 RCT, assessing self-management intervention programme specifically designed to target anxiety and depression
among stroke survivors. Excluded from review as participants were not required to have a clinical diagnosis of
anxiety to be eligible
Ihle-Hansen 2014 RCT, assessing multi-disciplinary interventions to target and reduce risks of further vascular incident among
stroke survivors. Included secondary outcome assessment of HADS. Excluded from review as participants were
not required to have a clinical diagnosis of anxiety to be eligible
Immink 2014 RCT, assessing yoga for stroke survivors. Included assessment of anxiety, but excluded from review as partici-
pants were not required to have a clinical diagnosis of anxiety to be eligible
Jouzi 2010 RCT, assessing massage therapy given to stroke survivors. Included assessment of anxiety, but excluded from
review as participants were not required to have a clinical diagnosis of anxiety to be eligible
Karaiskos 2012 RCT, assessing pharmacological agents administered to stroke survivors. Included assessment of anxiety, but
excluded from review as participants were not required to have a clinical diagnosis of anxiety to be eligible
Kimura 2003 Assessing pharmacological agent for stroke survivors with clinical diagnosis of moderate to severe depression
but excluded participants with GAD. Cohort study design; therefore excluded from review
Kongkasuwan 2014 RCT, assessing creative therapy combined with conventional rehabilitation programmes for stroke survivors.
Included assessment of anxiety, but excluded from review as participants were not required to have a clinical
diagnosis of anxiety to be eligible
Kulishova 2014 Assessing transcranial magnetic stimulation for stroke survivors. Information taken from English abstract only.
Does not appear to be an RCT. Assessment of anxiety is a secondary outcome and we have assumed that
participants were unlikely to be required to have a clinical diagnosis of anxiety; therefore we have excluded this
study
Li 2005 Assessing early functional training that included component of supportive treatment without antianxiety or
antidepressant prescriptions. Not an RCT, and intervention not compared against placebo or standard care;
therefore excluded from review
Liu 2004 RCT, assessing the use of pharmacological agents among stroke survivors with anxiety. However, agents were
not compared against placebo or standard care; therefore excluded from review
Mikami 2014 RCT, assessing effectiveness of an antidepressant on GAD, but not all participants were required to have GAD
for study inclusion; therefore we excluded this study
Mok 2004 RCT, assessing slow stroke back massage for stroke survivors. Included assessment of anxiety using Chinese
State Trait Anxiety Inventory, but participants were not required tomeet a cut-off criterion for anxiety; therefore
we excluded this study
Morrison 1998 Assessing use of a self-helpworkbook aimed at enhancing non-avoidant coping and increasing personal control
over recovery. Participants were stroke survivors and anxiety was assessed, but participants were not required
to have anxiety for eligibility. Study used a quasi-experimental cohort design; therefore we excluded this study
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(Continued)
Peng 2015 RCT, assessing a neuro-linguistic programme (NLP) intervention for stroke survivors. Included assessment
of anxiety and depression, but we excluded it from review as participants were not required to have a clinical
diagnosis of anxiety to be eligible
Rorsman 2006 RCT, assessing electroacupuncture and transcutaneous electrical nerve stimulation among stroke survivors.
Included assessment of anxiety, but excluded from review as participants were not required to have a clinical
diagnosis of anxiety to be eligible
Wu 2008 RCT, comparing alprazolam with acupuncture for stroke survivors with neurosis. Does not include comparison
against placebo or standard care; therefore excluded from this review
Wu 2012 RCT, assessing early psychological and physical rehabilitation programme. Included assessment of anxiety, but
excluded from review as participants were not required to have a clinical diagnosis of anxiety to be eligible
Xue 2013 RCT, assessing use of mecobalamine among stroke survivors. Currently published only as an abstract. Included
assessment of anxiety but not as a primary outcome. We have assumed therefore that participants were not
required to have a clinical diagnosis of anxiety to be eligible and have excluded this study
Ye 2006 RCT, comparison of pharmacological agents and rehabilitative training for stroke survivors with anxiety and
depression. Did not include comparison against placebo or standard care; therefore excluded from this review
GAD: generalised anxiety disorder
HADS: Hospital Anxiety and Depression Scale
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Doogan 2012
Methods Unclear if study is an RCT
Participants Stroke survivors
Interventions Inpatient rehabilitation programme to include psycho-education and relaxation
Outcomes Distress, before and after intervention
Notes Study is currently published only as an abstract. Information in abstract is insufficient to establish review eligibility.
No study author contact details in abstract. Attempted to source study author contact details through the university,
but no response to email enquiries
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Guilan 2013
Methods RCT
Participants Stroke survivors
Interventions Enhanced rehabilitation programme
Outcomes Self-rating of anxiety and depression as primary outcomes
Notes Study is currently published only as an abstract. No study author contact details in abstract and unable to source any
possible contacts for this study author. Information in abstract is insufficient to establish whether participants were
required to have a diagnosis of anxiety; therefore unable to assess if study meets review eligibility
Kerr 2014
Methods RCT, pilot study
Participants Stroke survivors
Interventions In-hospital intervention of early motivational interviewing
Outcomes HADS, Quality of Life Index
Notes Study is currently published only as an abstract. Information in abstract is insufficient to establish whether participants
were required to have a diagnosis of anxiety; therefore unable to assess if study meets review eligibility. No study
author contact details in abstract. Sourced possible email address through other publication, but no response to email
enquiries
Yates 2015
Methods RCT
Participants Stroke survivors
Interventions Guided computerised cognitive-behavioural therapy
Outcomes Beck Anxiety and Depression Inventories
Notes Study is currently published only as an abstract. Information in abstract is insufficient to establish whether participants
were required to have a diagnosis of anxiety; therefore unable to assess if study meets review eligibility
HADS: Hospital Anxiety and Depression Scale
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Pharmacological agents versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Dizziness 2 153 Risk Ratio (M-H, Random, 95% CI) 7.32 [0.96, 55.95]
Analysis 1.1. Comparison 1 Pharmacological agents versus control, Outcome 1 Dizziness.
Review: Interventions for treating anxiety after stroke
Comparison: 1 Pharmacological agents versus control
Outcome: 1 Dizziness
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wang 2005 7/54 0/27 51.8 % 7.64 [ 0.45, 128.93 ]
Zhang 2005 3/36 0/36 48.2 % 7.00 [ 0.37, 130.82 ]
Total (95% CI) 90 63 100.0 % 7.32 [ 0.96, 55.95 ]
Total events: 10 (Experimental), 0 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
1. stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc* or cva* or apoplexy* or SAH
2. (brain* or cerebr* or cerebell* or intracran* or intracerebral) near/5 (isch?emi* or infarct* or thrombo* or emboli* or occlus*)
3. (brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid) near/5 (haemorrhage* or hemorrhage* or haematoma*
or hematoma* or bleed*)
4. hemipleg* or hemipar* or paresis or paretic
5. brain injur*
6. #1 or #2 or #3 or #4 or #5
7. anxiety or anxieties or anxious or agoraphobi* or phobi* or panic disorder* or panic attack* or (obsess* near/3 compuls*) or post?
traumatic stress* or PTSD
8. feel* near/5 (apprehens* or dread or disaster* or fear* or worry or worried or terror)
9. “beck anxiety inventory” or “hamilton anxiety scale” or “hospital anxiety and depression scale” or “self-rating anxiety scale” or “state
trait anxiety inventory”
10. #7 or #8 or #9
Appendix 2. MEDLINE search strategy
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp
intracranial arterial diseases/ or exp “intracranial embolism and thrombosis”/ or exp intracranial hemorrhages/ or stroke/ or exp brain
infarction/ or vasospasm, intracranial/ or vertebral artery dissection/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiplegia/ or exp paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. brain injuries/ or brain injury, chronic/
8. or/1-7
9. anxiety/
10. anxiety disorders/ or agoraphobia/ or obsessive-compulsive disorder/ or panic disorder/ or phobic disorders/ or exp stress disorders,
traumatic/
11. exp Anti-Anxiety Agents/
12. (anxiety or anxieties or anxious or agoraphobi$ or phobi$ or panic disorder$ or panic attack$ or (obsess$ adj3 compuls$) or post?
traumatic stress$ or PTSD).tw.
13. (feel$ adj5 (apprehens$ or dread or disaster$ or fear$ or worry or worried)).tw.
14. manifest anxiety scale/
15. or/9-14
16. Randomized Controlled Trials as Topic/
17. random allocation/
18. Controlled Clinical Trials as Topic/
19. control groups/
20. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or
clinical trials, phase iv as topic/
21. double-blind method/
22. single-blind method/
23. Placebos/
24. placebo effect/
25. cross-over studies/
26. randomized controlled trial.pt.
27. controlled clinical trial.pt.
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28. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
29. (random$ or RCT or RCTs).tw.
30. (controlled adj5 (trial$ or stud$)).tw.
31. (clinical$ adj5 trial$).tw.
32. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
33. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
34. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
35. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
36. (cross-over or cross over or crossover).tw.
37. (placebo$ or sham).tw.
38. trial.ti.
39. (assign$ or allocat$).tw.
40. controls.tw.
41. or/16-40
42. exp animals/ not humans.sh.
43. 8 and 15 and 41
44. limit 43 to yr=“2010-Current”
Appendix 3. Embase search strategy
1. cerebrovascular disease/ or basal ganglion hemorrhage/ or exp brain hematoma/ or exp brain hemorrhage/ or exp brain infarction/ or
exp brain ischemia/ or exp carotid artery disease/ or cerebral artery disease/ or cerebrovascular accident/ or exp intracranial aneurysm/
or exp occlusive cerebrovascular disease/ or stroke/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. paralysis/ or hemiparesis/ or hemiplegia/ or paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. brain injury/
8. or/1-7
9. anxiety/
10. exp anxiety disorder/
11. exp anxiolytic agent/
12. (anxiety or anxieties or anxious or agoraphobi$ or phobi$ or panic disorder$ or panic attack$ or (obsess$ adj3 compuls$) or post?
traumatic stress$ or PTSD).tw.
13. (feel$ adj5 (apprehens$ or dread or disaster$ or fear$ or worry or worried or terror)).tw.
14. beck anxiety inventory/ or hamilton anxiety scale/ or “hospital anxiety and depression scale”/ or self-rating anxiety scale/ or state
trait anxiety inventory/
15. or/9-14
16. Randomized Controlled Trial/ or “randomized controlled trial (topic)”/
17. Randomization/
18. Controlled clinical trial/ or “controlled clinical trial (topic)”/
19. control group/ or controlled study/
20. clinical trial/ or “clinical trial (topic)”/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical
trial/
21. Crossover Procedure/
22. Double Blind Procedure/
23. Single Blind Procedure/ or triple blind procedure/
24. placebo/ or placebo effect/
25. (random$ or RCT or RCTs).tw.
26. (controlled adj5 (trial$ or stud$)).tw.
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27. (clinical$ adj5 trial$).tw.
28. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
29. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
30. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
31. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
32. (cross-over or cross over or crossover).tw.
33. (placebo$ or sham).tw.
34. trial.ti.
35. (assign$ or allocat$).tw.
36. controls.tw.
37. or/16-36
38. (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/) not
(human/ or normal human/ or human cell/)
39. 8 and 15 and 37
40. limit 39 to yr=“2010 -Current”
Appendix 4. CINAHL search strategy
1.(MH “Cerebrovascular Disorders”) OR (MH “Basal Ganglia Cerebrovascular Disease+”) OR (MH “Carotid Artery Diseases+”) OR
(MH “Cerebral Ischemia+”) OR (MH “Cerebral Vasospasm”) OR (MH “Intracranial Arterial Diseases+”) OR (MH “Intracranial
Embolism and Thrombosis”) OR (MH “Intracranial Hemorrhage+”) OR (MH “Stroke”) OR (MH “Vertebral Artery Dissections”)
2.TI ( stroke or poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex or SAH ) or AB ( stroke or
poststroke or post-stroke or cerebrovasc* or brain vasc* or cerebral vasc or cva or apoplex or SAH )
3.TI ( brain* or cerebr* or cerebell* or intracran* or intracerebral ) or AB ( brain* or cerebr* or cerebell* or intracran* or intracerebral )
4.TI ( ischemi* or ischaemi* or infarct* or thrombo* or emboli* or occlus* ) or AB ( ischemi* or ischaemi* or infarct* or thrombo* or
emboli* or occlus* )
5.S3 and S4
6.TI ( brain* or cerebr* or cerebell* or intracerebral or intracranial or subarachnoid ) or AB ( brain* or cerebr* or cerebell* or intracerebral
or intracranial or subarachnoid )
7.TI ( haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed* ) or AB ( haemorrhage* or hemorrhage* or haematoma*
or hematoma* or bleed* )
8.S6 AND S7
9.(MH “Hemiplegia”)
10.TI ( hemipleg* or hemipar* or paresis or paretic ) or AB ( hemipleg* or hemipar* or paresis or paretic )
11.(MH “Brain Injuries”) OR (MH “Head Injuries”)
12.TI (brain or head or intracran* or cerebr* or cerebell*) N5 (injur* or contusion* or hypoxi* or damage* or inflamm* or concussion
or trauma$ or fractur* or neoplasm* or lesion* or tumor* or tumour* or cancer* or infection*)
13.S1 OR S2 OR S5 OR S8 OR S9 OR S10 OR S11 OR S12
14.(MH “Anxiety”) OR (MH “Anxiety Disorders”) OR (MH “Fear”)
15.TX (taylor manifest anxiety scale) or TX “state trait anxiety inventory”
16.TX (anxiet* or anxious or agoraphobi* or phobi* or panic disorder* or panic attack* or (obsess* N3 compuls*) or post?traumatic
stress* or PTSD)
17.TX (feel* N5 (apprehens* or dread or disaster* or fear* or worr* or terror))
18.S14 OR S15 OR S16 OR S17
19.(MH “Randomized Controlled Trials”) or (MH “Random Assignment”) or (MH “Random Sample+”)
20.(MH “Clinical Trials”) or (MH “Intervention Trials”) or (MH “Therapeutic Trials”)
21.(MH “Double-Blind Studies”) or (MH “Single-Blind Studies”) or (MH “Triple-Blind Studies”)
22.(MH “Control (Research)”) or (MH “Control Group”) or (MH “Placebos”) or (MH “Placebo Effect”)
23.(MH “Crossover Design”) OR (MH “Quasi-Experimental Studies”)
24.PT (clinical trial or randomized controlled trial)
25.TI (random* or RCT or RCTs) or AB (random* or RCT or RCTs)
26. TI (controlled N5 (trial* or stud*)) or AB (controlled N5 (trial* or stud*))
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27.TI (clinical* N5 trial*) or AB (clinical* N5 trial*)
28.TI ((control or treatment or experiment* or intervention) N5 (group* or subject* or patient*)) or AB ((control or treatment or
experiment* or intervention) N5 (group* or subject* or patient*))
29.TI ((control or experiment* or conservative) N5 (treatment or therapy or procedure or manage*)) or AB ((control or experiment*
or conservative) N5 (treatment or therapy or procedure or manage*))
30.TI ((singl* or doubl* or tripl* or trebl*) N5 (blind* or mask*)) or AB ((singl* or doubl* or tripl* or trebl*) N5 (blind* or mask*))
31.TI (cross-over or cross over or crossover) or AB (cross-over or cross over or crossover)
32.TI (placebo* or sham) or AB (placebo* or sham)
33.TI trial
34.TI (assign* or allocat*) or AB (assign* or allocat*)
35.TI controls or AB controls
36.TI (quasi-random* or quasi random* or pseudo-random* or pseudo random*) or AB (quasi-random* or quasi random* or pseudo-
random* or pseudo random*)
37.S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33
OR S34 OR S35 OR S36
38.S13 AND S18 AND S37
Appendix 5. PsycINFO search strategy
1. cerebrovascular disorders/ or cerebral hemorrhage/ or exp cerebral ischemia/ or cerebral small vessel disease/ or cerebrovascular
accidents/ or subarachnoid hemorrhage/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiparesis/ or hemiplegia/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. brain injur$.tw.
8. or/1-7
9. exp anxiety/
10. exp anxiety disorders/ or panic/ or panic attack/ or fear/
11. anxiety management/
12. state trait anxiety inventory/ or taylor manifest anxiety scale/
13. (anxiety or anxieties or anxious or agoraphobi$ or phobi$ or panic disorder$ or panic attack$ or (obsess$ adj3 compuls$) or post?
traumatic stress$ or PTSD).tw.
14. (feel$ adj5 (apprehens$ or dread or disaster$ or fear$ or worry or worried or terror)).tw.
15. or/9-14
16. 8 and 15
17. random sampling/
18. experiment controls/
19. placebo/
20. (empirical study or treatment outcome clinical trial).md.
21. clinical trials/ or Treatment Effectiveness Evaluation/
22. random$.tw.
23. (controlled adj5 (trial$ or stud$)).tw.
24. (clinical$ adj5 trial$).tw.
25. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
26. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
27. ((multicenter or multicentre or therapeutic) adj5 (trial$ or stud$)).tw.
28. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
29. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
30. (coin adj5 (flip or flipped or toss$)).tw.
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31. (cross-over or cross over or crossover).tw.
32. placebo$.tw.
33. sham.tw.
34. (assign$ or alternate or allocat$ or counterbalance$ or multiple baseline).tw.
35. controls.tw.
36. (treatment$ adj6 order).tw.
37. or/17-36
38. 16 and 37
WH A T ’ S N E W
Date Event Description
7 September 2016 New search has been performed We updated all searches. We included in the review 1
new study with 21 participants. The review now in-
cludes 3 studies with 196 participants. We added a
’Summary of findings’ table and updated the results to
reflect outcome measures
7 September 2016 New citation required but conclusions have not
changed
We made no change to the conclusions of the review.
We added new review authors (Sharon R Lewis and
Ho-Yan Y Chun) to the review
C O N T R I B U T I O N S O F A U T H O R S
Peter Knapp is a senior lecturer and an applied health researcher. C Alexia Campbell Burton is a healthcare value consultant, John
Holmes is a senior lecturer in old age liaison psychiatry, Jenni Murray is a senior research fellow in complex health services research,
David Gillespie is a practising clinical psychologist, C. Elizabeth Lightbody is a reader in health services research, Caroline L Watkins
is a nursing professor of stroke and care of older people, Ho-Yan Y Chun is a clinical academic fellow, and Sharon R Lewis is a research
associate for systematic reviews of health interventions.
For the first published version of the review (Campbell Burton 2011): Campbell Burton co-ordinated and led the review. All review
authors contributed to drafting of the protocol. Campbell Burton and Knapp carried out independent screening of papers and formed
consensus on studies for inclusion in the review. Murray and Campbell Burton independently extracted data. Campbell Burton
conducted data entry and analysis and wrote the first draft of the review. All review authors contributed to the final draft.
For the updated review: Knapp led the review, Lewis co-ordinated the review, and Chun and Lewis carried out independent screening
of papers and, with Knapp, formed consensus on studies for inclusion in the review. Chun and Lewis independently extracted data.
Lewis conducted data entry and analysis and wrote the first draft of the review. All review authors contributed to the final draft.
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D E C L A R A T I O N S O F I N T E R E S T
Peter Knapp: none known.
C. Alexia Campbell Burton: none known.
John Holmes: none known.
Jenni Murray: none known.
David Gillespie: none known.
C. Elizabeth Lightbody: none known.
Caroline L Watkins: none known.
Ho-Yan Y Chun: none known.
Sharon R Lewis: none known.
S O U R C E S O F S U P P O R T
Internal sources
• University of Leeds, UK.
External sources
• NIHR Cochrane Programme Grant, UK.
13/89/16. ’Back to normal’: speed and quality of recovery after surgery, major injury and critical care. This funding supported the
work of Sharon Lewis
• CSO Clinical Academic Fellowship (CAF/15/07) awarded to Dr Yvonne Chun during the period of the review update, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For this update, we did not search the Allied and Complementary Medicine Database (AMED) or the Proquest Digital Dissertations
database. We did not search conference proceedings other than those searched for the Cochrane Stroke Group trials register, nor
PscyBITE (Psychological database for Brain Impairment Treatment Efficacy), and we did not contact the Association of the British
Pharmaceutical Industry.
We produced a ’Summary of findings’ table for this update, for the first seven primary and secondary outcomes. We edited the ’Results’
section to add narrative data under subheadings for each outcome.
I N D E X T E R M S
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Medical Subject Headings (MeSH)
Anti-Anxiety Agents [therapeutic use]; Antidepressive Agents [adverse effects; therapeutic use]; Anxiety [etiology; ∗therapy]; Buspirone
[therapeutic use]; Depression [therapy]; Paroxetine [adverse effects; therapeutic use]; Pilot Projects; Psychotherapy; Randomized Con-
trolled Trials as Topic; Relaxation Therapy [methods]; Stroke [∗psychology]
MeSH check words
Humans; Middle Aged
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